← All trials
NCT02560948
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2015
- Primary completion
- Aug 1, 2016
- Completion date
- Aug 1, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 654
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- ASIT Biotech S.A.Lead sponsor
- University of StrasbourgOverall official - principal investigator
- University of PilsenOverall official - principal investigator
- University of MilanOverall official - principal investigator
- Universitair Ziekenhuis GentOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.